Advances in the treatment and prevention of severe viral bronchiolitis.
Viral bronchiolitis continues to be a major public health problem. Prevention of severe RSV-associated bronchiolitis has been achieved in high-risk infants by passive administration of the humanized monoclonal anti-RSV-F antibody, palivizumab. Development of more potent anti-RSV neutralizing antibodies is underway, and vaccine development continues to progress. Supportive therapy is the mainstay for the treatment of established infection while new antiviral and anti-inflammatory strategies are being explored in preclinical trials.
Domachowske
Joseph B
JB
Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Rosenberg
Helene F
HF
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D001990:Bronchiolitis, Viral / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D007223:Infant; D000069455:Palivizumab; D018184:Paramyxoviridae Infections / Q000517:prevention & control; D010372:Pediatrics / Q000379:methods* / Q000639:trends*; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control; D014765:Viral Vaccines / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D007136:Immunoglobulins; D014765:Viral Vaccines; D000069455:Palivizumab